title: Value of novel agents and intensive therapy for patients with multiple myeloma.
abstract: We conducted a retrospective evaluation of response and survival for 293 patients with multiple myeloma treated since June 2000 with primary thalidomide- or bortezomib-based combinations, of whom 207 patients received intensive therapy supported by autologous blood stem cells within the first year. Survival times were calculated after a landmark of 1 year from start of therapy, so that subsequent median survival was 8.9 years for patients with CR, 4.9 years for those with PR and 0.6 year for patients with NR (P<0.001). Multivariate analyses confirmed CR or PR as the major favorable factors with less impact on prognosis for age or disease stage. Both novel agents and high-dose therapy (HDT) resulted in high frequencies of PR or CR, with early HDT useful for many patients with NR or PR in improving response status and subsequent survival.
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: R
authors: R
authors: Alexanian
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: M
authors: M
authors: Wang
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: K
authors: K
authors: Delasalle
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: S
authors: S
authors: Wang
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: M
authors: M
authors: Qazilbash
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: B
authors: B
authors: Handy
authors: University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors: D
authors: D
authors: Weber
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib